title: Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.
abstract: OBJECTIVE
  Treatment of chronic hepatitis C with interferon can be ineffective due to relapse. We aimed to reduce the 40% relapse rate of 6 months interferon-ribavirin combination therapy by prolonging treatment to 18 months.
  
  
  METHODS
  Three hundred patients with treatment-naive hepatitis C, were randomized to 18 months combination therapy with interferon (3MU tiw) and ribavirin (1000-1200 mg/day), 18 months interferon combined with placebo, or 6 months combination therapy with interferon and ribavirin, in a double blinded manner. All 295 patients who received at least one dose of treatment were included in the intention to treat analysis.
  
  
  RESULTS
  At the end of treatment, HCV RNA was undetectable in 55 and 49% of those on 6 and 18 months combination therapy, respectively, versus 26% of those on monotherapy (P<0.001). The relapse rate was 38% for 6 months combination therapy, 38% for 18 months monotherapy, and only 13% for 18 months combination treatment (P=0.002). The sustained response rates were 34% for 6 months combination therapy, 16% for 18 months monotherapy and 43% for 18 months combination therapy (P<0.05).
  
  
  CONCLUSIONS
  Reduction of relapse rates to 15% or less is feasible by prolongation of interferon-ribavirin treatment to 18 months.
authors.affiliation: Department of Hepatogastroenterology, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Johannes T
authors.initials: JT
authors.lastname: Brouwer
authors.forename: Frederik
authors.initials: F
authors.lastname: Nevens
authors.forename: Frank C
authors.initials: FC
authors.lastname: Bekkering
authors.forename: Nadine
authors.initials: N
authors.lastname: Bourgeois
authors.forename: Hans
authors.initials: H
authors.lastname: Van Vlierberghe
authors.forename: Christine J
authors.initials: CJ
authors.lastname: Weegink
authors.forename: Véronique
authors.initials: V
authors.lastname: Lefebvre
authors.forename: Jan
authors.initials: J
authors.lastname: Van Hattum
authors.forename: Jean
authors.initials: J
authors.lastname: Henrion
authors.forename: Jean
authors.initials: J
authors.lastname: Delwaide
authors.forename: Bettina E
authors.initials: BE
authors.lastname: Hansen
authors.forename: Solko W
authors.initials: SW
authors.lastname: Schalm
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin